Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
Open Access
- 1 March 2010
- journal article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 17 (1), 241-253
- https://doi.org/10.1677/erc-09-0200
Abstract
Interleukin-6 (IL-6) is suggested to have a pathogenic role in the progression of prostate cancer (PC), therefore representing an attractive target for new therapies. However, due to the pleiotropy of this cytokine, targeting IL-6 results in different and unpredictable responses. In order to better understand the mechanisms underlying the different responses to the cytokine, we focused our attention on IL-6 receptors (IL-6Rs) that represent the first element in the cascade of cytokine-activated signalling pathways. IL-6 signal transduction may indeed occur through the membrane IL-6R (classical signalling) and/or through the less studied soluble IL-6R (sIL-6R; IL-6 trans-signalling (IL-6TS)). We provide the first evidence how responses to IL-6 may depend on the different content of IL-6Rs in PC. In particular, the studies of 3H-thymidine incorporation and exploitation of different approaches (i.e. activation or inhibition of IL-6TS in sIL-6R-negative and -positive cell lines and transfection of IL-6R siRNA) allowed us to demonstrate that IL-6TS specifically accounts for an anti-proliferative effect of the cytokine in three PC cell lines that are known to respond differently to IL-6. Additionally, by applying migration-, scratch- and adhesion assays, we show that IL-6TS increases motility and migration and decreases adhesion of prostate cells facilitating thereby processes that determine metastasis initiation and spread. Finally, by western analyses, we uncovered an IL-6- and sIL-6R-dependent downregulation of the tumour suppressor maspin. Collectively, these data suggest that selective targeting of IL-6TS might allow to refine the currently available experimental anti-IL-6 therapies against PC.Keywords
This publication has 57 references indexed in Scilit:
- Emerging therapies in castrate-resistant prostate cancerCurrent Opinion in Oncology, 2009
- Maspin reduces prostate cancer metastasis to boneUrologic Oncology: Seminars and Original Investigations, 2008
- Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based BiomarkersClinical Cancer Research, 2008
- Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cellsFree Radical Biology & Medicine, 2007
- Interleukin-6 and its receptor: from bench to bedsideMedical Microbiology and Immunology, 2006
- Interleukin-6 biology is coordinated by membrane bound and soluble receptors.Acta Biochimica Polonica, 2003
- Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasisProceedings of the National Academy of Sciences of the United States of America, 2003
- The role of transsignalling via the agonistic soluble IL-6 receptor in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2002
- Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasisUrology, 2001
- Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial CellsScience, 1994